The Changing Multidisciplinary Treatment Landscape in Severe Asthma
This CME-accredited CME Snapshot™ four-part series is intended for primary care providers, including internists, family physicians, nurse practitioners, and physician assistants involved in the ongoing management of patients with severe asthma. The faculty will review freely available patient- and caregiver-directed educational resources that seek to improve shared decision-making and multidisciplinary care.
This activity has been designed to meet the educational needs of primary care providers, including internists, family physicians, nurse practitioners, and physician assistants, involved in the ongoing management of patients with severe asthma.
Upon completion of this activity, participants will be better able to do the following:
- Describe the mechanisms of action and clinical profiles of cytokine-targeting biologic medications for the treatment of severe asthma
- Personalize multidisciplinary management plans for patients with severe asthma to reflect exacerbation risks, treatment responses, patient preferences, and shared decision-making
Jonathan Corren, MD
Barbara P. Yawn, MD, MSc, FAAFP
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
|Jonathan Corren, MD|
Speakers’ Bureau: AstraZeneca; Genentech, Inc.; Teva Pharmaceutical Industries Ltd.
Consultant/Advisor: AstraZeneca; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC
Research Grant: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Stallergenes Greer plc
|Barbara P. Yawn, MD, MSc, FAAFP||Consultant/Advisor: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation|
Non-faculty: Rose O’Connor, PhD, CHCP; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from AstraZeneca.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, and AstraZeneca do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Non-physician